GEn1E Lifesciences YC 지원서

Summer 2019Active

GEn1E Lifesciences은(는) Summer 2019 배치에서 Healthcare 회사로 Y Combinator를 거쳤습니다. 아래에는 회사의 사업 내용, 창립자, 그리고 실제 YC 양식에 맞춰 재구성한 YC 지원서가 있습니다.

YC 배치: Summer 2019
산업: HealthcareTherapeutics
상태: Active
출시됨: 2022

창업자

Ritu LalFounder

GEn1E Lifesciences의 사업 내용

GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities - creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital - a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.

GEn1E Lifesciences의 YC 지원서, 재구성됨

Y Combinator 지원

GEn1E Lifesciences, Summer 2019 기수. 공개 데이터를 기반으로 작성된 실제 지원 질문.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

GEn1E Lifesciences

Describe what your company does in 50 characters or less.

AI platform accelerating therapies for rare diseases

What is your company going to make? Please describe your product and what it does or will do.

We are building an AI platform that speeds up discovery and development of novel immunomodulatory therapies targeting multiple mechanisms at once. Our platform identifies and optimizes protein therapies for rare and inflammatory diseases with no current treatments. We've already developed a lead candidate for ARDS and a pipeline of 21+ selective immunomodulators.

Where do you live now, and where would the company be based after YC?

We live in Palo Alto, CA, and the company is based here.

Explain your decision regarding location.

Palo Alto puts us at the center of biotech and AI innovation, with access to top talent, investors, and collaborators. It's also where we're rooted personally and professionally.

전체 지원서에서 21개의 추가 답변

Founders, Progress, Idea, Equity, Curious, Batch Preference는 전체 버전에 있습니다. 무료 계정을 만들어 YC Insights에서 모든 YC 배치 옆에 열어보세요.

전체 지원 보기

자주 묻는 질문

GEn1E Lifesciences의 실제 YC 지원서인가요?

아닙니다. Y Combinator는 제출된 지원서를 비공개로 유지합니다. 이것은 재구성된 것입니다. 실제 YC 양식 질문에 GEn1E Lifesciences의 공개 데이터(출시 노트, 창업자 배경, 제품 설명)를 기반으로 답변했습니다. GEn1E Lifesciences과 같은 회사가 YC에 어떻게 자신을 소개하는지 보여주며, 그들이 제출한 텍스트는 아닙니다.